Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Dose Escalation Question

<< Previous

Bullboard Posts

Next >>

Comment by AMoschittoon Apr 28, 2021 11:16am

73 Views

Post# 33082344

RE:RE:Dose Escalation Question

So Patient 1 in Gettysburg (being first dosed in early March) has probably had their 3rd dose.* So this would be the 3rd dose on the escalation schedule, is that right?

*3rd dose assumes the 3 week dosing schedule that Dr. Shah mentions in the article.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023